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Individuals with MCI declined in performance over 6 months in the Clock-drawing (Clox 1) and the WAIS Digit Span tests, but
not in the Dementia Rating Scale (DRS). Individual performance on Clox 1 and Digit Span did not correlate after 6 months.
Performance on the Digit Span Test also did not correlate with the DRS, but performance on Clox 1 correlated with the DRS.
Performance in Clox 1 was, therefore, not a predictor of performance in the Digit Span Test. These findings support the use of a
test battery containing the Digit Span test to detect and track cognitive decline in MCI.
Mild cognitive impairment (MCI) is a condition character-
ized by subjective cognitive complaints and objective evi-
dence of cognitive deficits beyond that anticipated according
to age and education, yet is accompanied by preservation of
functional abilities [1, 2]. As such, individuals with MCI are
neither cognitively normal nor are they demented. However,
MCI is frequently prodromal to Alzheimer’s disease (AD)
[2], to the extent that MCI has been referred to as early-stage
AD [3], and clinical manifestation of AD has been recently
subdivided into the stage of mild cognitive impairment
(MCI) and the subsequent stage of dementia [4]. In this
regard, improved ability to detect the earliest stages of MCI
and AD are essential; probably more people than currently
detected would benefit from treatment [5–8]. Multiple
nonstandardized factors compound early detection, includ-
ing the variance inherent in initial screening by a family
physician/general practitioner [9], diﬀerential diagnosis due
to comparison of an individual’s performance with diﬀerent
normative groups [10], and the heterogeneous nature of
MCI [11]. While early detection of cognitive impairment is a
daunting task in general, detection of continued decline may
be achievable for individuals with MCI since the cognitive
performance of such individuals is already being monitored.
Several studies have demonstrated that the use of multi-
ple tests was superior in identification of MCI than was any
single test. Such test batteries include the Mini-Mental State
Examination (MMSE) [12], the Royal Clock-Drawing test
(Clox 1) [13], the Cognitive Capacity Screening Examination
(CCSE), the Cognitive Assessment Battery [14–17], as well
as novel tests such as Diagnostic characteristics of the Mini-
Cog, and a new 50-point test based on expanding selected
MMSE items (MMX) [18]. Unfortunately, even though
currently utilized tests may accurately diagnose MCI, they do
not always predict of the course or eventual outcome of MCI
[14]. Accordingly, improved methods are still required not
only for initial detection, but also to monitor subtle cognitive
change among populations that may predict a transition
from MCI to AD.
We present information herein indicating that three tests
(Clox 1, the WAIS Digit Span test, and the Dementia Rating
Scale-2) provide diﬀerential information on cognitive per-
formance in MCI. Individual performance did not correlate
among these tests. Our findings suggest that the WAIS Digit
Span test, a sensitive and easily administered test, should be
incorporated into a test battery for diagnosis and monitoring
of MCI.
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Figure 1: Performance on Clox 1, WAIS Digit Span, and the DRS. The change in value for each individual’s performance on each test was
calculated at 3- and 6-months. Values represent the mean change (± standard error of the mean). The mean performance at baseline was
normalized to 0 for each test to allow comparison among tests. Values for Clox 1 diﬀered statistically from baseline by 3 months. Values for
the Digit Span did not diﬀer statistically from baseline until 6 months. Values for the DRS did not diﬀer statistically from baseline at either
time point.
Participants included 10 community-dwelling individu-
als (mixed gender, 72 ± 4.3 years of age with 13.5 ± 3 years
of education) with an independent diagnosis of MCI who
had been randomly assigned to a placebo group under blind
conditions as part of a clinical study of a nutraceutical
supplement (to be published). Two of these participants
withdrew from the study for reasons unrelated to the study
itself. Participants completed the Royal Clock-Drawing test
(Clox 1) [13, 16], the WAIS Digit-Span test [19], and the
Dementia Rating Scale (DRS-2; Psychological Assessment
Resources; http://www4.parinc.com/) at enrollment into the
study, and 3 and 6 months later. All tests were administered
by the same individual. All procedures were approved by the
Knox College IRB.
The deltas of individual performance were compared
using paired t tests. To determine whether or not there was
any correlation among performance on these tests, scores
of individuals on each test at 3 and 6 month intervals were
plotted as a function of each other (e.g., Clox 1 versus total
score of the DRS) and a regression line obtained [16].
The participant pool at baseline obtained 87 ± 5%
of the maximum possible score on Clox 1, 71 ± 7% of
the maximum possible score on the WAIS Digit-Span test
(combined forward and backwards scores; no diﬀerence was
detected in forward versus backward scores), and 94± 3% of
the maximum possible score on the total DRS, with a range
of 91–98% among the various domains of the DRS.
Participants on average displayed a progressive decline in
performance in Clox 1 and Digit Span Test over the following
6 months. The decline was more pronounced after 3 months
for Clox 1 than for the Digit Span Test, but a similar level
of decline for both tests was observed after 6 months. By
contrast, no decline was detected in the DRS over 6 months
(Figure 1).
The group performance in Clox 1 and the Digit Span Test
displayed similar overall declines over 6 months (Figure 1).
However, comparison of the performance of individual
participants demonstrated distinct diﬀerences (Table 1). Par-
ticipants 1–3 declined in the Digit Span test, while they
either improved or maintained performance on Clox 1.
This represents 38% of the total participants. Only a single
participant declined in both of these tests, and the remaining
50% declined in Clox 1 while improving or maintaining
performance in the Digit Span test. Graphing of performance
on the Clox 1 test as a function of performance on the Digit-
Span test demonstrated a lack of correlation of these tests
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Figure 2: Comparison of individual performance on Clox 1, the WAIS Digit Span and the DRS Each individual’s performance on one test
was plotted as a function of the other, and a regression line was determined.
(Figure 2). Two participants (1 and 3) that declined in the
Digit Span, while improving in Clox 1 also declined in DRS
(Table 1). One participant (6) declined in both Clox 1 and
DRS (but improved in the Digit Span test). The remaining
participants (63% of the total) improved in the DRS while
either declining or maintaining their performance on Clox 1.
These findings indicate that an individual’s performance in
Clox 1 was not necessarily a predictor of performance in the
Digit Span Test. Individual performance on the Digit Span
Test also did not correlate with performance on the DRS
at 6 months. By contrast, individual performance on Clox 1
correlated with performance on the DRS after 6 months
(Figure 2).
The lack of correlation of the decline observed in the
Digit Span test with those of either Clox 1 or the DRS
indicates that the WAIS Digit Span Test may provide an indi-
cation of decline in cognitive performance not necessarily
revealed by either Clox 1 or DRS. It was not anticipated that
an individual’s performance on Clox 1 and the Digit Span test
would not correlate at 6 months, since average performance
on both of these tests presented a similar decline at 6
months. Similarly, it was not anticipated that an individual’s
performance on Clox 1 would correlate with that on the
DRS at 6 months, since the average performance on Clox 1
had declined but that on the DRS had not. These findings
collectively indicate that diﬀerent aspects of cognitive decline
can be revealed by these tests, and that averages of groups can
obscure the presence of such declines for individuals.
One interpretation of this phenomenon is that the Clox 1
test, despite its inherent complexity, is contextual, while the
Digit Span test is not. The nature of the Clox 1 test is to
Table 1: Change of individual performance on Clox 1, WAIS Digit
Span, and the DRS. The change in value for each individual’s
performance on each test over 6 months. Values represent the per-
formance at 6monthsminus the respective performance at baseline.
Participant Clox 1 Digit Span DRS
1 3 −4 −2
2 0 −3 3
3 1 −2 −6
4 −2 0 3
5 −5 −2 3
6 −3 1 −2
7 −6 0 2
8 −2 1 1
determine whether or not an individual can visualize a clock,
follow a series of instructions, and execute the “change of
set” of the designated time to positioning of the hands on the
clock [13]. Mildly impaired individuals, however, may draw
a clock essentially from long-term memory rather than as a
series of steps, and perhaps only display minor diﬃculty with
spacing of numbers and/or placement of hands. The DRS
also incorporates contextual memory and/or performance
in each of its domains The Digit Span test, by contrast, has
no context and relies entirely on short-term memory. In
this regard, providing a context for random digits, such as
speaking the series with the cadence of a telephone number
with area code, a social security number, or a zip code, might
generate improved performance. A similar comparison could
be devised using either random letters versus letters that
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eventually spell out familiar words or groups of words
that form a simple sentence. Contextual memory may also
influence performance on repeat tests, which could not be
achieved with the random nature of the Digit Span test.
The findings presented herein were observed among
while we were conducting a multisite, follow-up study of a
vitamin/nutraceutical formulation previously demonstrated
to maintain or improve cognitive performance prior to and
during AD (to be published). This ongoing study encom-
passes a wide range of cognitive impairment, including
individuals with MCI and all stages of AD whether or not
they are currently receiving pharmacological interventions or
initiate additional interventions during the study. As such,
there was no inherent goal to determine which if any of our
test instruments was more appropriate for any given stage of
cognitive impairment. Rather, we utilized a battery of stan-
dard tests that our previous studies suggested would be useful
for a range of cognitive impairment, and moreover provide
comparative information among clusters of participants
displaying various degrees of cognitive impairment. The dif-
ferences in individual versus group decline in these tests were
a serendipitous finding, which we report herein in the event
that other investigators may wish to consider incorporating
the WAIS Digit Span Test into their own respective test
battery for MCI. It is unfortunate that we did not conduct
the MMSE at baseline, which would allow us to determine
whether or not the Wais Digit Span test correlated with the
MMSE. The MMSE has been demonstrated to correlate well
with both the Clock-drawing test and the DRS [16, 20].
These findings demonstrate that the Clox 1 test was the
most sensitive in detecting cognitive decline, but neverthe-
less, the Digit Span test and the DRS identified cognitive
decline in some participants that was not detected by the
Clox 1 test. Our findings support the notion that a battery
of tests, which encompass a variety of tasks, may maximize
early detection and helpmonitor cognitive change during the
course of MCI [14, 16].
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